# Phase 2/3 carcinoma trials recruiting: 60 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 60 trials in phase 2/3 for carcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2/3 carcinoma trials: 60 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2-3/carcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 60
- Recruiting or not yet: 60
- Read on: November 19, 2026

## Trials

The 25 newest of 60, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 5, 2026 | NCT07920549 | A Randomized Trial of Standard vs. Hypofractionated Accelerated Radiotherapy for Progression in Limited-Stage Small Cell Lung Cancer | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2/3 | Not yet recruiting | Limited Stage Small-Cell Lung Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07920549) |
| October 22, 2026 | NCT07888075 | Master Protocol for the Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or... | AVEO Pharmaceuticals, Inc. | Phase 2/3 | Not yet recruiting | Cachexia; Cancer, Cachexia, Cachexia-Anorexia Syndrome, Metastatic Colorectal Cancer (CRC), Metastatic Non-small Cell... | 950 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07888075) |
| October 8, 2026 | NCT07865910 | A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With... | Shanghai Henlius Biotech | Phase 2/3 | Not yet recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 1,438 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07865910) |
| September 11, 2026 | NCT07815665 | A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic... | Summit Therapeutics | Phase 2/3 | Recruiting | Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) | 800 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07815665) |
| July 22, 2026 | NCT07718737 | Global, Multicenter Study of AMT-116 Versus Investigator's Choice in Participants With Advanced or Metastatic Non-squamous EGFR-Wildtype... | Multitude Therapeutics Inc. | Phase 2/3 | Recruiting | NSCLC (Advanced Non-small Cell Lung Cancer) | 512 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07718737) |
| June 23, 2026 | NCT07662811 | SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer | Shanghai Chest Hospital | Phase 2/3 | Not yet recruiting | Non-Small Cell Lung Cancer | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662811) |
| June 23, 2026 | NCT07662395 | SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer | Sinocelltech Ltd. | Phase 2/3 | Recruiting | Double Blind | 410 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07662395) |
| June 17, 2026 | NCT07653451 | Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer | Peking University Cancer Hospital & Institute | Phase 2/3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07653451) |
| June 11, 2026 | NCT07642024 | A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Non-small Cell Lung Cancer | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07642024) |
| June 9, 2026 | NCT07636226 | QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer | Sun Yat-sen University | Phase 2/3 | Not yet recruiting | Small Cell Lung Cancer | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636226) |
| April 28, 2026 | NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line... | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 2/3 | Recruiting | Esophageal Squamous Cell Carcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554456) |
| March 24, 2026 | NCT07490262 | A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as... | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Phase 2/3 | Recruiting | Hepatocellular Carcinoma (HCC) | 680 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07490262) |
| February 27, 2026 | NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF... | Cancer Research UK | Phase 2/3 | Recruiting | Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type, Neoplasms... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07440290) |
| February 6, 2026 | NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Phase 2/3 | Not yet recruiting | Hepatocellular Carcinoma (HCC) | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07392866) |
| January 26, 2026 | NCT07365319 | A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung... | Eikon Therapeutics | Phase 2/3 | Recruiting | Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | 750 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07365319) |
| December 30, 2025 | NCT07309419 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable... | Shanghai Zhongshan Hospital | Phase 2/3 | Not yet recruiting | Hepatocellular Carcinoma | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07309419) |
| December 19, 2025 | NCT07293468 | Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) | Tuen Mun Hospital | Phase 2/3 | Recruiting | Hepatocellular Carcinoma (HCC) | 106 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07293468) |
| December 16, 2025 | NCT07285850 | The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD | Eastern Hepatobiliary Surgery Hospital | Phase 2/3 | Recruiting | HCC - Hepatocellular Carcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285850) |
| November 26, 2025 | NCT07251062 | A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. | CSPC Megalith Biopharmaceutical Co.,Ltd. | Phase 2/3 | Not yet recruiting | Esophageal Squamous Cell Carcinoma | 737 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07251062) |
| November 12, 2025 | NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy and With Tarlatamab, Alone... | Pfizer | Phase 2/3 | Recruiting | Small Cell Lung Cancer (SCLC) | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07226999) |
| October 8, 2025 | NCT07213375 | High Dose Dexamethasone to Reduce Postoperative Pain After Video-Assisted Thoracoscopic Surgery Lobectomy /Segmentectomy | Copenhagen University Hospital, Rigshospitalet | Phase 2/3 | Recruiting | Analgetic, Lung Cancer (NSCLC), Video Assisted Thoracic Surgery (VATS), Glucocorticoid | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07213375) |
| September 4, 2025 | NCT07155187 | A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination... | AbbVie | Phase 2/3 | Recruiting | Non-Small Cell Lung Cancer, c-MET | 490 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07155187) |
| September 2, 2025 | NCT07149649 | Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) | Swiss Cancer Institute | Phase 2/3 | Recruiting | Metastatic NSCLC - Non-Small Cell Lung Cancer | 230 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07149649) |
| August 20, 2025 | NCT07131319 | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | Second Affiliated Hospital of Nanchang University | Phase 2/3 | Recruiting | Non-Small Cell Lung Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07131319) |
| August 19, 2025 | NCT07129993 | Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally... | Daiichi Sankyo | Phase 2/3 | Recruiting | Urothelial Cancer, Bladder Cancer | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07129993) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Sun Yat-sen University | 4 |
| Cancer Research UK | 3 |
| Shanghai Zhongshan Hospital | 3 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| Peking Union Medical College Hospital | 2 |
| Swiss Cancer Institute | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| [Hansoh BioMedical R&D Company](https://specstream.ai/data/clinical-trials/company/hansoh-biomedical-r-and-d-company) | 1 |
| Shanghai Chest Hospital | 1 |
| UNICANCER | 1 |
| Vasgene Therapeutics, Inc | 1 |
| London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 1 |
| [Bristol-Myers Squibb](https://specstream.ai/data/clinical-trials/company/bristol-myers-squibb) | 1 |
| Intergroupe Francophone de Cancerologie Thoracique | 1 |
| Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | 1 |
| Guangxi Medical University | 1 |
| Inhibrx Biosciences, Inc | 1 |
| Tuen Mun Hospital | 1 |
| TuHURA Biosciences, Inc. | 1 |
| Tata Memorial Centre | 1 |
| [Mirati Therapeutics Inc.](https://specstream.ai/data/clinical-trials/company/mirati-therapeutics-inc) | 1 |
| [AbbVie](https://specstream.ai/data/clinical-trials/company/abbvie) | 1 |
| Second Affiliated Hospital of Wenzhou Medical University | 1 |
| [CSPC Megalith Biopharmaceutical Co.,Ltd.](https://specstream.ai/data/clinical-trials/company/cspc-megalith-biopharmaceutical-co-ltd) | 1 |
| Zhujiang Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 31 |
| United States | 14 |
| France | 10 |
| Italy | 8 |
| United Kingdom | 8 |
| Australia | 7 |
| Germany | 7 |
| Spain | 7 |
| Japan | 6 |
| Taiwan | 6 |
| Belgium | 6 |
| Poland | 6 |
| South Korea | 6 |
| Romania | 5 |
| Switzerland | 4 |
| Canada | 4 |
| Argentina | 4 |
| Austria | 4 |
| Chile | 3 |
| Greece | 3 |
| India | 3 |
| Netherlands | 3 |
| Thailand | 3 |
| Bulgaria | 3 |
| Brazil | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Child psychiatry practices in the United States](https://specstream.ai/data/businesses/child-psychiatry-practices/united-states)
- [Video production companies in the United States](https://specstream.ai/data/businesses/video-production-companies/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
- [Home security companies in the United States](https://specstream.ai/data/businesses/home-security-companies/united-states)
- [Closet remodeling companies in the United States](https://specstream.ai/data/businesses/closet-remodeling-companies/united-states)
- [Water utilities in the United States](https://specstream.ai/data/businesses/water-utilities/united-states)
